A wire-service report published on 21 October 2026 says cheap Chinese antibiotic ingredients are threatening the penicillin manufacturing Europe still has at Sandoz’s Kundl plant in Austria. Sandoz filed an anti-dumping complaint with the European Commission in March, arguing that Chinese amoxicillin ingredients are sold in Europe below production cost. That is the company’s allegation, and testing it is the job of a formal investigation that has not, to our knowledge, been opened.
Key takeaways: penicillin manufacturing Europe and the trade case
- Sandoz says Kundl is the only European plant making penicillin from start to finish, including key ingredients.
- Eurostat figures cited in the report show China’s share of EU penicillin and derivative imports at 86% last year, up from 44% in 2019.
- The Commission declined to comment on the complaint; the report says a probe is expected, with timing unclear because of a backlog of cases.
- Duties are one possible outcome, not a reported one. The report notes the EU has also reached negotiated outcomes with Beijing in another sector.
- The debate over penicillin manufacturing Europe needs to be judged on evidence a probe would gather, which is not yet public.
How an anti-dumping investigation works
General background: under EU trade defence rules, the Commission can examine whether goods imported from a non-EU country are sold at less than their normal value and whether that harms EU producers. A complaint from the industry usually starts the process. If the Commission opens an investigation, it collects data from producers and importers, and it can impose provisional and then definitive duties if it finds dumping and injury. The Commission’s trade policy site describes the instruments in detail.
Such investigations normally take around a year or longer, and a complaint does not automatically lead to one. The report says a backlog is delaying the Commission, and that of 23 ongoing EU anti-dumping and anti-subsidy investigations, all but three target China, alone or jointly. We have not verified that count independently.
What the report says is at stake
The Kundl site employs more than 2,000 people, according to the report, and makes penicillin by fermentation in large metal vats. Sandoz says up to 90% of global antibiotic active ingredients are produced outside Europe, mainly in China or in India using Chinese chemicals. Europe’s exports of penicillins and derivatives are now about one-fifth of their early-2000s peak. Our own arithmetic on the Eurostat shares puts the rise in China’s import share at 42 percentage points between 2019 and last year; the figures are from the Eurostat data cited in the report and we have not checked the table.
The report also says Sandoz told UK lawmakers that Kundl’s capacity is not commercially sustainable without higher government payments, and that the plant has received public money before: €50 million within a €200 million expansion about three years ago, plus a €28.3 million Commission-approved aid package in 2023. These are reported figures attributed to the company and the report.
Reported facts versus possible outcomes for penicillin manufacturing Europe
It helps to keep two lists apart. What follows in the first list has been reported; the second list is our own, labelled sketch of what could happen and has no confirmation from the companies or the Commission.
- Reported: a Sandoz complaint filed in March; a Commission that declined comment; a probe described as expected but not scheduled; Chinese officials who say disputes should be settled through dialogue.
- Possible, not reported: the Commission opens an investigation and later imposes duties; the Commission opens a probe that ends without duties; the Commission does not proceed; or public support for Kundl rises instead of, or alongside, trade measures.
- Also possible: any duties change the price Europe’s health systems pay for amoxicillin ingredients, which is a trade-off the report does not quantify.
Our analysis
In our assessment, the penicillin manufacturing Europe wants to protect is a strategic asset, but a trade case is a narrow tool for protecting it. An anti-dumping finding turns on pricing and injury evidence, while the broader worry, dependence on one supplier country, is a policy question about resilience that tariffs alone do not resolve. Sandoz has commercial reasons to press both arguments.
The opposing view is that healthcare buyers benefit from low prices and that duties could pass through into higher costs. Both positions have merit, which is why the evidence collected in a probe matters. For related reporting see our pharmaceutical coverage.
What is not disclosed about penicillin manufacturing Europe’s trade case
- The contents of the Sandoz complaint and the cost data behind it.
- Whether and when the Commission will open an investigation.
- The response of Chinese producers to the below-cost allegation.
- Kundl’s annual output and its share of European demand.
Risks and caveats for penicillin manufacturing Europe
This article rests on one wire-service report and on statements attributed to Sandoz, Chinese officials and others. There is no regulatory finding of dumping. The penicillin manufacturing Europe could keep or lose depends on facts outside this report, including energy costs and procurement rules, so readers should not treat any single figure here as a forecast. For background on why antibiotics matter to health systems, see the World Health Organization antimicrobial resistance fact sheet.
The report also quotes security analysts who say China’s market power gives it leverage and that the risk should be taken seriously. Those are opinions and not evidence of intent, and the Chinese foreign ministry, as reported, says it opposes protectionism.
What to watch next for penicillin manufacturing Europe
- A notice in the EU Official Journal opening any anti-dumping proceeding.
- Eurostat’s next release on penicillin and derivative trade.
- Sandoz commentary on Kundl’s economics and any new public support.
- Whether other European producers join the complaint, which would strengthen the case that penicillin manufacturing Europe-wide is at risk. See also Abbott Gets FDA Approval for CardioMEMS HF System Upgrade With CardioGuide HF App.
FAQ
What is Sandoz asking the European Commission to do?
It filed an anti-dumping complaint in March about Chinese amoxicillin ingredients, which it says are sold in Europe below production cost.
Has the Commission opened an investigation?
None has been reported. The Commission declined to comment, and the report says timing is unclear.
Would duties fix the problem for penicillin manufacturing Europe relies on?
Duties would address pricing, but not every cause of Kundl’s difficulties, such as energy costs. Whether they would be imposed is unknown.
How we reported this: we relied on a wire-service report and on trade-policy background from official sources, attributing every figure. Calculations are labelled as ours. Last updated 23 October 2026. This is news reporting and not advice.
